Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort

Jennifer L. St. Sauver, Aruna V. Sarma, Debra J. Jacobson, Michaela E. McGree, Michael M. Lieber, Cynthia J. Girman, Ajay Nehra, Steven J. Jacobsen

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS). Higher levels of C-reactive protein (CRP) may therefore be associated with the development of these outcomes. The authors examined the association of CRP levels measured in 1996 with rapid increases in prostate volume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (through 2005) in a population-based cohort of men residing in Olmsted County, Minnesota. Men with CRP levels of ≥3.0 mg/L were more likely to have rapid increases in irritative LUTS (odds ratio (OR)=2.14, 95% confidence interval (CI): 1.18, 3.85) and rapid decreases in peak flow rates (OR=2.54, 95% CI: 1.09, 5.92) compared with men with CRP levels of <3.0 mg/L. CRP levels were not significantly associated with rapid increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels. Associations were attenuated after adjusting for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR = 2.45, 95% CI: 0.73, 8.25). These results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.

Original languageEnglish (US)
Pages (from-to)1281-1290
Number of pages10
JournalAmerican journal of epidemiology
Volume169
Issue number11
DOIs
StatePublished - Jun 2009

Keywords

  • C-reactive protein
  • Inflammation
  • Prostatic hyperplasia
  • Signs and symptoms
  • Urinary tract

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort'. Together they form a unique fingerprint.

Cite this